Corticosteroids for severe community-acquired pneumonia: Time to change clinical practice

Annals of Internal Medicine

Volumn 163, Issue 7, 2015, Pages 560-561

  Restrepo, Marcos I ^a   Anzueto, Antonio ^a   Torres, Antoni ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CORTICOSTEROID; HYPERTENSIVE FACTOR; MACROLIDE; METHYLPREDNISOLONE; PLACEBO;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; CLINICAL PRACTICE; COMMUNITY ACQUIRED PNEUMONIA; CORTICOSTEROID THERAPY; EDITORIAL; HOSPITALIZATION; HUMAN; INFLAMMATION; META ANALYSIS (TOPIC); MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); ADJUVANT CHEMOTHERAPY; COMMUNITY-ACQUIRED INFECTIONS; COMPLICATION; FEMALE; MALE; MIDDLE AGED; PNEUMONIA;

ADRENAL CORTEX HORMONES; CHEMOTHERAPY, ADJUVANT; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; PNEUMONIA;

EID: 84943377413     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M15-1805     Document Type: Editorial

References (10)

1. DeFrances CJ, Lucas CA, Buie VC, Golosinskiy A. 2006 National Hospital Discharge Survey. Natl Health Stat Report. 2008:1-20.
2. Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al; CDC EPIC Study Team. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015. [PMID: 26172429]
3. Montón C, Ewig S, Torres A, El-Ebiary M, Filella X, Rañó A, et al. Role of glucocorticoids on inflammatory response in nonimmuno-suppressed patients with pneumonia: a pilot study. Eur Respir J. 1999;14:218-20. [PMID: 10489855]
4. Sibila O, Ferrer M, Agustí C, Torres A. Corticosteroids as adjunc-tive treatment in community-acquired pneumonia. Minerva Anest-esiol. 2014;80:1336-44. [PMID: 24518215]
5. Confalonieri M, Urbino R, Potena A, Piattella M, Parigi P, Puccio G, et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med. 2005;171:242-8. [PMID: 15557131]
6. Snijders D, Daniels JM, de Graaff CS, van der Werf TS, Boersma WG. Efficacy of corticosteroids in community-acquired pneumonia: a randomized double-blinded clinical trial. Am J Respir Crit Care Med. 2010;181:975-82. [PMID: 20133929] doi:10.1164/rccm.200905 -0808OC
7. Siemieniuk RAC, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia. A systematic review and meta-analysis. Ann Intern Med. 2015;163:519-28. doi:10.7326/M15 -0715
8. Menéndez R, Martínez R, Reyes S, Mensa J, Filella X, Marcos MA, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009;64:587-91. [PMID: 19131448] doi:10.1136/thx.2008.105312
9. Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Re-spir Crit Care Med. 2012;186:657-65. [PMID: 22744718] doi:10 .1164/rccm.201203-0487OC
10. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015;313: 677-86. [PMID: 25688779] doi:10.1001/jama.2015.88